Aside from the general population, the COVID-19 pandemic has also affected a group of patients in palliative oncology care. In this study, long-term immune responses against SARS-CoV-2 after vaccination were monitored in a cohort of patients in palliative oncology care. This non-randomized, prospective, and open-label pilot study recruited patients from the Palliative Oncology Program and included 147 patients, of which 80 were females (54.4%) and 67 males (45.6%). The overall evaluation included current health status, SARS-CoV-2 anti-S IgG titer, and neutralizing antibodies using the SARS-CoV-2 virus neutralization test (VNT). Anti-S IgG antibody analysis revealed high (H) antibody levels in 35.7% (n = 10) and very high (VH) levels in 39.3% (n = 11) of patients after the second vaccination dose. Similarly, after the third dose, H was found in 29.6% (n = 32) and VH in 55.5% (n = 60) of patients. High and very high anti-S IgG antibody levels were consistent with high VNT titers (>2560) and H antibody levels in 17.1% (n = 12) or VH in 82.9% (n = 58) of patients. Patients with two or more doses showed H and VH antibody levels at a median of 451 and 342 days after vaccination, respectively. In this clinical trial, patients showed high and very high levels of anti-S IgG antibodies over a longer period of time. These patients did not show reduced immunological responses to the COVID-19 vaccine challenge. We can assume that prevention through vaccination can reduce the risk of complications or death from COVID-19 in patients in early palliative oncology care.

Department of Epidemiology Military Medical Faculty University of Defense 500 01 Hradec Kralove Czech Republic

Department of Oncology and Radiotherapy University Hospital Hradec Kralove 500 05 Hradec Kralove Czech Republic

Institute of Clinical Microbiology Faculty of Medicine in Hradec Kralove Charles University 500 03 Hradec Kralove Czech Republic

Institute of Clinical Microbiology University Hospital Hradec Kralove 500 05 Hradec Kralove Czech Republic

Zobrazit více v PubMed

Merad M., Blish C.A., Sallusto F., Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375:1122–1127. doi: 10.1126/science.abm8108. PubMed DOI

Mohseni Afshar Z., Hosseinzadeh R., Barary M., Ebrahimpour S., Alijanpour A., Sayad B., Hosseinzadeh D., Rouhollah Miri S., Sio T.T., Sullman J.M.S., et al. Chalanges posed by COVID-19 in cancer patients: A narrative review. Cancer Med. 2022;11:1119–1135. doi: 10.1002/cam4.4519. PubMed DOI PMC

Bakitas M.A., Tosteson T.D., Li Z., Lyons K.D., Hull J.G., Li Z., Dione-Odom N., Frost J., Dragnev H.K., Hegel T.M., et al. Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III Randomized controlled trial. Clin. Oncol. 2015;33:1438–1445. doi: 10.1200/JCO.2014.58.6362. PubMed DOI PMC

Dai Y.-M., Huang Y.-T., Lai M.-Y., Liu H.-E., Shiao C.-C. Optimal timing for hospice-shared care initiation in terminal cancer patients. Support. Care Cancer. 2021;29:6871–6880. doi: 10.1007/s00520-021-06284-9. PubMed DOI

Radbruch L., Knaul F.M., De Lima L., De Joncheere C., Bhadelia A. The key role of palliative care in response to the COVID-19 tsunami of suffering. Lancet. 2020;395:1467–1469. doi: 10.1016/S0140-6736(20)30964-8. PubMed DOI PMC

Boechat J.L., Chora I., Morais A., Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology—Current perspectives. Pulmonology. 2021;27:423–437. doi: 10.1016/j.pulmoe.2021.03.008. PubMed DOI PMC

Vabret N., Britton G.J., Gruber C., Hegde S., Kim J., Kuksin M., Levantovsky R., Malle L., Moreira A., Park M.D., et al. Immunology of COVID-19: Current State of the Science. Immunity. 2020;52:910–941. doi: 10.1016/j.immuni.2020.05.002. PubMed DOI PMC

Anka A.U., Tahir M.I., Abubakar S.D., Alsabbagh M., Zian Z., Hamedifar H., Sabzevari A., Azizi G. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. Scand. J. Immunol. 2021;93:e12998. doi: 10.1111/sji.12998. PubMed DOI PMC

Caturegli G., Materi J., Howard B.M., Caturegli P. Clinical validity of serum antibodies to SARS-CoV-2: A case-control study. Ann. Intern. Med. 2020;173:614–622. doi: 10.7326/M20-2889. PubMed DOI PMC

Sakurai A., Sasaki T., Kato S., Hayasgi M., Sei-Ichiro T., Ishihara T., Iwata M., Morise Z., Doi Y. Natural history of asymptomatic SARS-CoV-2 infection. N. Engl. J. Med. 2020;383:885–886. doi: 10.1056/NEJMc2013020. PubMed DOI PMC

Perkmann T., Perkman-Nagele N., Koller T., Mucher P., Radakovics A., Marculescu R., Woltz M., Wagner F.O., Binder C.J., Haslacher H. Anti-spike protein assays to determine SARS-CoV-2 antibody levels: A head-to-head comparison of five quantitative assays. Microbiol. Spectr. 2021;9:e0024721. doi: 10.1128/Spectrum.00247-21. PubMed DOI PMC

Padoan A., Cosma C., Bonfante F., Della Rocca F., Barbaro F., Santarossa C., Dall´Olmo L., Pagliari M., Bortolami A., Cattelan A., et al. Neutralizing antibody titres six months after Comirnaty vaccination kinetics and comparison with SARS-CoV-2 immunoassays. Clin. Chem. Lab. Med. 2021;60:456–463. doi: 10.1515/cclm-2021-1247. PubMed DOI

Favresse J., Gillot C., Di Chiaro L., Eucher C., Elsen M., Van Eeckhoudt S., David C., Morimont L., Dogné J.-M., Douxfils J. Neutralizing antibodies in COVID-19 patients and vaccine recipients after two doses of BNT162b2. Viruses. 2021;13:1364. doi: 10.3390/v13071364. PubMed DOI PMC

Post N., Eddy D., Huntley C., Van Schalkwyk I.C.M., Shrotri M., Leeman D., Rigby S., Williams V.S., Bermingham W.H., Kellam P., et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE. 2021;15:e0244126. doi: 10.1371/journal.pone.0244126. PubMed DOI PMC

Wang Z., Muecksch F., Schaefer-Badajev D., Finkin S., Viant C., Gaebler C., Hoffmann H.H., Barnes C.O., Cipolla M., Ramos V., et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595:426–431. doi: 10.1038/s41586-021-03696-9. PubMed DOI PMC

Baldo P., Fornasier G., Ciolfi L., Sartor I., Francescon S. Pharmacovigilance in oncology. Int. J. Clin. Pharm. 2018;40:832–841. doi: 10.1007/s11096-018-0706-9. PubMed DOI PMC

Yu W.-D., Sun G., Li J., Xu J., Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 2019;452:66–70. doi: 10.1016/j.canlet.2019.02.048. PubMed DOI

Desai A., Gainor J.F., Hegde A., Schram M.A., Curigliano G., Pal S., Liu V.S., Halmos B., Groisberg R., Grade E., et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat. Rev. Clin. Oncol. 2021;18:313–319. doi: 10.1038/s41571-021-00487-z. PubMed DOI PMC

Schmidt A.L., Labaki C., Hsu C.Y., Bakouny Z., Berg S.A., Blau S., Daher A., El Zarif T., Friese C.R., Griffiths A.E., et al. COVID-19 vaccination and breakthrough infection in patients with cancer. Ann. Oncol. 2022;33:340–346. doi: 10.1016/j.annonc.2021.12.006. PubMed DOI PMC

Choueiri T.K., Labaki C., Bakouny Z., Hsu C.-Y., Schmidt A.L., De Lima Lopes G., Jr., Hwang C., Singh K.R.S., Jani C., Weissmann L.B., et al. Breakthrough SRS-CoV-2 infections among patients with cancer following two and three doses of covid-19 mRNA vaccines: A retrospective observational study from the COVID-19 and cancer consortium. Lancet Reg. Health Am. 2023;19:100445. PubMed PMC

Subbiah V.A. Global effort to understand the riddles of COVID-19 and cancer. Nat. Cancer. 2020;1:943–945. doi: 10.1038/s43018-020-00129-w. PubMed DOI

Desai A., Gupta R., Advani S., Ouellette L., Kuderer N.M., Lyman G.H., Li A. Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta- analysis of cohort studies. Cancer. 2021;127:1459–1468. doi: 10.1002/cncr.33386. PubMed DOI

Desai A., Sachdeva S., Parekh T., Desai R. COVID-19 and cancer: Lessons from a pooled meta-analysis. JCO Glob. Oncol. 2020;6:557–559. doi: 10.1200/GO.20.00097. PubMed DOI PMC

Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S.M., Rivera R.D., Shete S., Hsu C.-Y., Desai A., De Lima Lopes G., Jr., et al. Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study. Lancet. 2020;395:1907–1918. doi: 10.1016/S0140-6736(20)31187-9. PubMed DOI PMC

Strang P. Palliative oncology and palliative care. Mol. Oncol. 2022;16:3399–3409. doi: 10.1002/1878-0261.13278. PubMed DOI PMC

Hetherington L., Johnsaton B., Kotronoulas G., Finlay F., Keeley P., McKeown A. COVID-19 and hospital palliative care—A service evaluation exploring the symptoms and outcomes of 186 patients and the impact of the pandemic on specialist hospital palliative care. Pall. Med. 2020;34:1256–1262. doi: 10.1177/0269216320949786. PubMed DOI PMC

Bausewein C., Hodiamont F., Berges N., Ullrich A., Gerlach C., Oechsle K., Pauli B., Weber J., Stiel S., Schneider N., et al. National strategy for palliative care of severely ill and dying people and their relatives in pandemics (PallPan) in Germany—Study protocol of mixed-methods project. BMC Pall. Care. 2022;21:10. doi: 10.1186/s12904-021-00898-w. PubMed DOI PMC

Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment. Int. J. Oncol. 2019;54:407–419. doi: 10.3892/ijo.2018.4661. PubMed DOI PMC

Grana C., Ghosn L., Evrenoglou T., Jarde A., Minozzi S., Bergman H., Buckley B.S., Probyn K., Villanueva G., Henschke N., et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst. Rev. 2022;12:CD0154477. PubMed PMC

Fendler A., De Vries E.G., Geurtsvan-Kessel C.H., Haanen J.B., Wörmann B., Turajlic S., van Lilienfeld-Toal M. COVID-19 vaccines in patients with cancer: Immunogenicity, efficacy and safety. Nat. Rev. Clin. Oncol. 2022;19:385–401. doi: 10.1038/s41571-022-00610-8. PubMed DOI PMC

Scherrens A.L., Cohen J., Mahieu A., Deliens L., Deforche B., Beernaert K. The perception of people with cancer of starting a conversation about palliative care: A qualitative interview study. Eur. J. Cancer Care. 2020;29:e13282. doi: 10.1111/ecc.13282. PubMed DOI

Bandieri E., Borelli E., Gilioli F., Bigi S., Mucciarini C., Ferrari U., Eliardo S., Pinto L., Porro C.A., Efficace F., et al. Stigma of palliative care among patients with advanced cancer and their caregivers on early palliative care. Cancers. 2023;15:3656. doi: 10.3390/cancers15143656. PubMed DOI PMC

Mukai K., Tsunoda H., Imai R., Numata A., Kida K., Oba K., Yagishita K., Yamauchi H., Kanomata N., Kurihara Y. The location of unilateral axillary lymphadenopathy after COVID-19 vaccination compared with that of metastasis from breast cancer without vaccination. Jpn. J. Radiol. 2023;41:617–624. doi: 10.1007/s11604-023-01387-1. PubMed DOI PMC

Martinez-Cannon B.A., Garcia-Ronquillo K., Leon-Rodriguez E. Vaccination status and attitudes towards COVID-19 vaccination in patients undergoing active cancer treatment in a referral center in Mexico: A survey study. Support. Care Cancer. 2023;31:209. doi: 10.1007/s00520-023-07667-w. PubMed DOI PMC

Piler P., Thon V., Andrýsková L., Dolezel K., Kostka D., Pavlík T., Dusek L., Pikhart H., Bobak M., Matic S., et al. Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population. Commun. Med. 2022;2:19. doi: 10.1038/s43856-022-00080-0. PubMed DOI PMC

Thon V., Piler P., Pavlík T., Andrysova L., Dolezel K., Kostka D., Pikhart H., Bobak M., Klamova J. Investigation of SARS-CoV-2 seroprevalence in relation to natural infection and vaccination between October 2020 and September 2021 in the Czech Republic: A prospective national cohort study. BMJ Open. 2023;13:e068258. doi: 10.1136/bmjopen-2022-068258. PubMed DOI PMC

Grivas A., Khaki A.R., Wise-Draper T.M., French B., Hennessy C., Hsu C.Y., Shyr Y., Li X., Choueiri T.K., Painter C.A., et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: A report from the COVID-19 and cancer consortium. Ann. Oncol. 2021;32:787–800. doi: 10.1016/j.annonc.2021.02.024. PubMed DOI PMC

Ali H., Alahmad B., Al-Shammari A.A., Alterki A., Hammad M., Cherian P., Alkhairi I., Sindhu S., Thanaraj T.A., Mohammad A., et al. Previous COVID-19 infection and antibody levels after vaccination. Front. Public Health. 2021;9:778234. doi: 10.3389/fpubh.2021.778243. PubMed DOI PMC

Glück V., Grobecker S., Köstler J., Tydykov L., Bertok M., Weidlich T., Gottwald C., Salzberger B., Wagner R., Zeman F., et al. Immunity after COVID-19 and vaccination: Follow-up study over 1 year among medical personnel. Infection. 2022;50:439–446. doi: 10.1007/s15010-021-01703-9. PubMed DOI PMC

Rank A., Tzortzini A., Kling E., Schmid C., Claus R., Löll E., Burger R., Römmele C., Dhillon C., Müler K., et al. One year after mild COVID-19: The majority of patients maintain specific immunity, but one in four still suffer from long-term symptoms. J. Clin. Med. 2021;10:3305. doi: 10.3390/jcm10153305. PubMed DOI PMC

Sarrigeorgiou I., Moschandreou D., Dimitriadis A., Tsinti G., Sotiropoulou E., Ntoukaki E., Eliadis P., Backovic M., Labropoulou S., Escriou N., et al. Combined monitoring if IgG and IgA anti-spike and anti-receptor binding domain long term responses following BNT162b2 mRNA vaccination in Greek healthcare workers. PLoS ONE. 2022;17:e0277827. doi: 10.1371/journal.pone.0277827. PubMed DOI PMC

Choj H.-W., Jung Y., Kim U.J., Lee S.-C., Kwon J.H., Kim H., Kim S., Lee Y., Shim H.-J., Cho S.-H., et al. Comparative study on the immunogenicity of COVI-19 mRNA vaccines in patients receiving adjuvant and palliative chemotherapy. Cho. Med. J. 2024;60:69–77. PubMed PMC

Tran S., Truong H.T., Narendran A. Evaluation of COVIDE-19 vaccine response in patients with cancer: An interim analysis. Eur. J. Cancer. 2021;159:259–274. doi: 10.1016/j.ejca.2021.10.013. PubMed DOI PMC

Caramujo C., Gomes I., Fraga T., Paulo J., Broco S., Cunha N., Madeira P., Carvalho T., Teixeira M., Sousa G. Immune response to SARS-CoV-2 Vaccination in cancer patients: A prospective study. Cureus. 2023;15:e37014. doi: 10.7759/cureus.37014. PubMed DOI PMC

Fajfr M., Pajer P., Ruzek D., Sleha R., Janovska S., Bohonek M., Kabickova H., Kubicková P., Stefanik M., Strakova P., et al. Multicentric evaluation of sensitivity of eight commercial anti-SARS-CoV-2 antibody assays and their correlation to virus neutralisation titers in seropositive subjects. Sci. Rep. 2024;14:1421. doi: 10.1038/s41598-024-51968-x. PubMed DOI PMC

Schwedler C., Grzeski M., Kappert K., Rust J., Heymann G., Hoppe B., Blanchard V. Coronavirus disease 2019—Related alteration of total and anti-spike IgG glycosylation in relation to age and anti-spike IgG titer. Front. Microbiol. 2022;13:775186. doi: 10.3389/fmicb.2022.775186. PubMed DOI PMC

Limbu Y.B., Gautam K.R. The determinants of COVID-19 vaccination intention: A meta-review. Front. Public Health. 2023;11:e1162861. doi: 10.3389/fpubh.2023.1162861. PubMed DOI PMC

Pradani K.I.P., Weerasekara I., Damayanthi H.D.W.T. COVID-19 vaccine acceptance and hesitancy among patients with cancer: A systematic review and meta-analysis. Front. Public Health. 2022;212:66–75. doi: 10.1016/j.puhe.2022.09.001. PubMed DOI PMC

Xie Z., Tak-Fai Lau J., Liang Y., Ouyang Q., Chen J., Lin S., Yao K., Hu X., Lin H., Yu Y., et al. Prevalence and factors of COVID-19 vaccine refusal among solid cancer patients in China: An application of the health belief model. Front. Public Health. 2023;11:e1236376. doi: 10.3389/fpubh.2023.1236376. PubMed DOI PMC